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Abstract 
Background: Smoking is the leading preventable cause of death around the world. Arab 
populations have traditionally high smoking rates, and the influx of Arab immigrants to countries 
around the world can amplify the health disparities in this population. Primary care providers in 
areas with prominent Arab populations must develop a clear understanding of how to provide 
cessation support in a culturally appropriate and effective manner. 
Objectives: To review the literature on the efficacy and comparative effectiveness of smoking 
cessation interventions for Arab adults living in the Middle East.  
Eligibility Criteria: English language smoking cessation trials at clinics treating adult Arab 
smokers in Middle Eastern countries with follow-up after at least 6 months;	 behavioral, 
pharmacological, and combined interventions were eligible. 
Data Sources: PubMed and Scopus were systematically searched for relevant articles published 
between January 1990 and December 2015.  
Data Abstraction: One reviewer abstracted relevant data and performed a quality assessment of 
each included study. 
Data Synthesis: The review of the literature yielded 517 unique titles and abstracts; 46 abstracts 
appeared eligible and were reviewed at the full-text stage. Of these, 7 studies met full eligibility 
criteria; 2 were rated as good quality and the others were rated as fair quality. Studies enrolled 
populations from Arab countries and interventions were generally set in outpatient settings. Two 
were randomized trials and five were pre-post studies. One study assessed a pharmacological 
intervention and all others assessed combination therapy. Studies assessed a range of 
pharmacologic agents, including: centrally-acting medicines (varenicline and bupropion), and 
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nicotine replacement therapies, including nicotine patches, gum, and tablets. Behavioral 
interventions included brief counseling, seminars, weekly meetings, and follow-up activities. 
Limitations: A small body of literature was available, with very few randomized trials. 
Interventions and enrolled populations were heterogeneous, which made comparisons of quit 
rates difficult. This review’s scope only included English articles.  
Conclusions and Implications of Key Findings: Using nicotine gum had a statistically significant 
improvement compared with the naltrexone and clonidine interventions at 6 months (RR 6.31; 
95% CI 2.65, 15.06). 59 No difference was found between the patches, gum, and tablets groups at 
12 months. However, the use of patches and gum had a statistically significant improvement 
compared to a single nicotine replacement therapy (RR 1.86; 95% CI 1.28, 2.72). 58 In the 5 pre-
post studies, quit rates from baseline ranged from 12.9% to 34.6% over 6 months to 5 years.  In 
Middle Eastern countries, additional research is needed regarding cultural components of 
interventions and methods of behavioral work. The development of culturally appropriate 
smoking cessation programs is vital for the provision of holistic care to Arab migrants and 
refugees.  
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Introduction 
 Cigarette smoking harms nearly every organ of the body, making it one of the biggest 
public health threats worldwide. Tobacco causes approximately half of its users to face a 
premature death, totaling at over six million deaths per year. 1 Furthermore, one billion tobacco-
related deaths are predicted during the 21st century with over half occurring before the age of 70. 
2 Clearly, morbidity and mortality rates attributed to tobacco use has reached a dangerous level. 
 The World Health Organization Framework Convention on Tobacco Control (WHO 
FCTC) promotes six proven public health strategies to reduce tobacco use worldwide. Known as 
MPOWER, these strategies include the following: (1) monitoring tobacco use and prevention 
policies, (2) protecting people from tobacco smoke, (3) offering help to quit tobacco use, (4) 
warning about the dangers of tobacco, (5) enforcing bans on tobacco advertising, promotion and 
sponsorship, and (6) raising tobacco taxes. 3 While these efforts have been very effective when 
targeting populations of Western ethnicity, use of tobacco products is increasing in less-
developed countries and ethnic groups.  
 This review seeks to evaluate the efficacy and comparative effectiveness of smoking 
cessation interventions among Arab adults living in Arabic countries. For the purpose of this 
review, countries defined as Arabic include Afghanistan, Bahrain, Iran, Iraq, Israel, Jordan, 
Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Syria, Turkey, the United Arab Emirates, and 
Yemen. The interventions that have shown efficacy in other populations, such as Americans, 
may be more or less effective in Arab populations due to cultural factors, social norms, access to 
health care, and policy control in Arab countries. The findings and discussion may inform 
primary care physicians who treat the Arab population living as refugees how to best provide 
smoking cessation support.  
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Harms of Smoking  
 Smokers face significantly increased health risks, and there is no risk-free level of 
exposure to tobacco. 4 Compared with nonsmokers, smokers are more likely to develop lung 
cancer, stroke, chronic obstructive pulmonary disease, and heart disease through mechanisms 
including DNA damage, inflammation, and oxidative stress. 2,5 Smoking increases the risk of 
coronary heart disease and stroke by 2 to 4 times and lung cancer by 25 times. 4 The risk of heart 
disease and cancer are currently leading causes of death in the US, both of which are primarily 
attributed to cigarette use. These conditions account for an estimated 50% of all deaths in the US, 
while the remaining eight leading causes combined account for only 25%.6 Smoking also causes 
significant morbidity related to other conditions such as asthma, digestive problems, gum 
disease, tuberculosis, vision problems, reduced fertility, and impotence. 2 Overall, the effects of 
these conditions and others may significantly reduce quality of life.  
There is also a significant impact on the health of a cigarette user’s family members and 
friends. Over 7,000 chemicals have been identified in secondhand smoke, and approximately 250 
of them have been labeled as harmful. 7 Exposure to secondhand smoke leads to an increase in 
endothelial dysfunction and inflammation, which cause a variety of health disparities, including 
acute cardiovascular events and thrombosis. 5 Secondhand smoke also increases a nonsmoker’s 
chance of developing cancer by 20 to 30%. There is no safe level of exposure to secondhand 
smoke.7 
 In addition to direct effects on the health of smokers, smoking contributes to increased 
health care utilization, heath care costs, and increased absenteeism from work. Estimated costs 
per year attributed to cigarette use exceed $300 billion in the US alone. 4 Due to the recent 
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denormalization of smoking, smokers are often stigmatized and discriminated against, which 
further reduces their quality of life. 8  
Smoking Cessation Interventions in the US 
Policy Interventions 
 While smoking is still a major public health threat, the decline of smoking in the US due 
to tobacco control efforts can be considered one of public health’s greatest accomplishments. 9 
The prevalence of cigarette smoking among adults decreased from 42% in 1965 to 18% in 2012. 
4 Policy in the US has acted as a primary force behind cessation efforts, as laws can be used to 
made tobacco products less accessible, less attractive, and less affordable. For example, in 1965 
the Federal Cigarette Labeling and Advertising Act was established which requires health 
warnings to be published on cigarette packages. In 1970, cigarette advertising on television and 
radio was prohibited through the Public Health Cigarette Smoking Act. In 1988, an amendment 
to the Federal Aviation Act made domestic flights of less than two hours smoke-free. In 2000, 
the Wendell H. Ford Aviation Investment and Reform Act extended this prohibition to all flights 
between the US and foreign destinations. 10 A decade later, the 2009 Family Smoking Prevention 
and Tobacco Control Act transferred the authority to regulate tobacco products to the U.S. Food 
and Drug Administration. This act also enforced user fees upon tobacco manufacturers, which 
will be used to support youth education on prevention and cessation. 11  
Medical Interventions 
 Healthcare settings are also important venues for delivering effective smoking cessation 
interventions, and are the focus of this review. Even with effective public health policies in 
place, many people struggle to quit tobacco. Nearly 70% of cigarette users reported wanting to 
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quit and over 50% made at least one attempt in the past 12 months. Only 3 to 6% of individuals 
who made an unaided attempt to quit were smoke-free one year later. 12  
 Much of the challenge in reaching abstinence can be attributed to the addicting nature of 
cigarettes. Nicotine is the key chemical compound in commercial tobacco products; it causes and 
sustains their powerful addicting effects. Upon inhalation, nicotine quickly travels through the 
bloodstream to the brain where it acts on multiple types of nicotinic receptors. 5 These receptors 
create temporary feelings of relaxation, stress relief, and mood improvement. However, the 
feelings are only temporary and when nicotine is not supplied withdrawal symptoms ensue. 13 
Cravings, anger, irritability, anxiety, depression, and weight gain are some symptoms among 
many others that smokers may struggle with when reducing their nicotine intake. 14  
 The addiction process and ensuing withdrawal symptoms can be alleviated through 
medical care. Among patients who comply with interventions provided by a clinician, over 30% 
of quit attempts are successful one year later. 15 Clinicians usually employ behavioral therapy, 
pharmacotherapy, or a combination of these two techniques. 
Behavioral Therapy 
 Behavioral treatment approaches include both individual and group counseling. 
Individual counseling plays an important role in helping smokers quit. Even a minimal 
intervention (e.g., one that lasts less than 3 minutes) can increase tobacco abstinence rates. 16,17 
Behavioral counseling may be complemented by telephone counseling, internet resources, and 
text messaging. Group therapy provides additional accountability and may include stress 
management or relaxation classes. 18 This method creates encouragement and support, two 
crucial components in encouraging health behavior change. 19 Behavioral therapy can be very 
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helpful and most studies have shown that individuals who utilize this technique experience 
increasing quit rates.20 
Pharmacotherapy 
 The two major types of pharmacotherapy include (1) nicotine replacement and (2) 
centrally-acting medications such as bupropion and varenicline. The US Public Health Service 
recommends nicotine patches combined with a short acting immediate release nicotine (e.g., 
gum, lozenge, inhaler, or nasal spray) as the first-line therapy. Nicotine replacement is available 
in various forms, including a transdermal nicotine patch, nicotine gum, lozenges, inhaler, and 
nasal spray. The patch creates a baseline protection by providing long-acting nicotine while 
options such as gum or lozenges release short-acting nicotine to handle cravings or other 
symptoms. The dosing of nicotine for each method is determined by the quantity of cigarettes 
smoked per day. 21,22 These methods allow the provision of nicotine without the harmful effects 
of tobacco, decreasing the individual’s nicotine withdrawal symptoms.  
Centrally acting agents have different mechanisms. Varenicline is a partial agonist of the 
alpha-4 beta-2 subunit of the nicotinic acetylcholine receptor. By partially binding to this 
receptor, symptoms of withdrawal are reduced and the rewards of smoking are blocked. 23 The 
mechanism of bupropion is unknown, but researchers suggest that it acts through dopaminergic 
and noradrenergic pathways as it can also be used as an antidepressant. 24  
Tobacco Use in Arabic Countries 
Smoking Status 
 Much of the success in decreasing smoking rates in the US is due to a revolutionary 
change in Americans’ collective view of smoking – it has converted from an accepted pastime to 
a threat to individual and public health. However, the previous decades of increased attention on 
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smoking morbidity and mortality primarily targeted White Americans. 25 Significant disparities 
in cigarette use remain across different races, ethnicities, educational levels, and socioeconomic 
statuses. The Arab population is one such minority who has not experienced this transformation 
in their perceptions of smoking.  
 Arab countries have some of the highest rates of smoking in the world. In a recent 
collection of tobacco control country profiles issued by the World Health Organization 
(summarized in Table 1), prevalence of cigarette use in some Arabic countries reached 66% for 
men and 30% for women. 26 Smoking is an acceptable social habit in the Middle East. A study in 
Jordan showed that 66% of residents expressed no smoking restrictions around family members 
or when hosting guests, despite 79% of study participants stating they understood the dangers of 
second-hand smoke. 27 Cultural norms may prevent smokers from acting on this knowledge, as 
offering a cigarette is often a sign of hospitality and smoking inside the home is customary. 25 
Beyond cultural influences, the declining cigarette consumption in areas such as the US has 
encouraged transnational tobacco companies to increase their sales efforts in the Middle East due 
to the lack of restrictions on tobacco advertising. 28 Without successful tobacco free policies 
similar to those in the US, Arabic countries are vulnerable to the pressures of both economic and 
media influences. This makes the availability of quality medical support in the quit attempt 
process even more important. 
 It is also important to note that tobacco use in the Middle East extends beyond the usual 
span of products found in the US, as regional tobacco use methods are becoming increasingly 
common. Water pipe use, also known as ‘narghile’, ‘hubble-bubble’, ‘sheesha’, ‘mada-a’, or 
‘goza’, has recently increased in prevalence, especially among youth and women. 29 A study 
performed in Kuwait found that 79.9% of water pipe smokers were women. 30 Because the  
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Table 1. Summary of WHO Tobacco Control Country Profiles for Arabic 
countries.31 
 
Area Smoking rate Pharmacy availability  Quit 
line 
Cessation 
support  
Insurance 
coverage Male Female NRTa Bupropion Varenicline 
Afghanis
tan 
N/A N/A Yes No No No None No coverage 
Bahrain 42.7 7.1 Yes With r/x With r/x No Most clinics, 
some 
hospitals 
Partial coverage 
for NRTs and 
cessation support 
Iran 22.4 1.0 Yes No No Yes Some clinics Full coverage for 
NRTs, partial 
coverage for 
cessation support 
Iraq N/A N/A Yes With r/x No No Some 
hospitals 
Full coverage for 
NRTs, partial 
coverage for 
cessation support 
Israel 41.5 19.8 Yes With r/x With r/x 
 
Yes Some clinics, 
and hospitals 
Partial coverage 
for NRTs and r/x, 
full coverage for 
cessation support 
Jordan  65.5 10.2 Yes No With r/x 
 
No Some clinics  Full coverage for 
NRTs and 
cessation support, 
partial coverage 
for varenicline  
Kuwait N/A N/A Yes No With r/x 
 
Yes Most clinics, 
hospitals and 
communities 
Partial coverage 
for NRTs, full 
coverage for 
cessation support 
Lebanon 43.9 29.9 Yes With r/x With r/x No Some 
hospitals 
Partial coverage 
for cessation 
support 
Oman 19.5 1.0 Yes No No No Some clinics Partial coverage 
for cessation 
support 
Qatar N/A N/A With 
r/x 
With r/x With r/x No Some clinics 
and hospitals 
Full coverage for 
everything 
Saudi 
Arabia 
26.8 3.0 Yes With r/x With r/x No Most clinic 
and hospitals 
Partial coverage 
for everything 
Syria N/A N/A No With r/x With r/x No Most clinics 
and hospitals 
Partial coverage 
for cessation 
support 
Turkey 41.6 13.2 Yes With r/x With r/x Yes Some clinics 
and hospitals 
Full coverage for 
NRTs, partial 
coverage for 
medications and 
cessation support 
UAE N/A N/A Yes With r/x Yes Yes Some clinics 
and most 
hospitals 
Partial coverage 
for everything 
Yemen N/A N/A Yes No No No None None 
a Nicotine replacement therapy  
 Abraham 12 
smoke is drawn through water, users often assume this decreases the health risks in comparison 
to cigarettes. However, this tobacco use method contains monoxide, tar, nicotine, heavy metals, 
and other toxic elements found in cigarettes. 27,32,33 Water pipe smoking carries the same or more 
Middle Eastern cultural overtones that have been identified in cigarette use. For example, some 
countries discourage youth from smoking cigarettes in social settings but allow water pipe 
smoking. 34 The differences in smoking habits among US populations and populations from 
Arabic countries suggests that culturally tailored cessation services may be more effective than 
standard interventions among Arabs living in the US. 
Smoking Cessation Interventions 
 Despite the strong cultural presence of smoking in Arabic countries and heavy 
broadcasting control, smokers in these countries are interested in cessation programs. In Syria, 
several studies showed that the rates of quit attempts were double the recorded rates in the US. 
However, the percentage of successful quit attempts is less than half the proportion in the US. 
35,36 This suggests an increased need for effective smoking cessation programs. Currently, only 
three out of the fifteen Arab countries offer the standard cessation therapies used in the US 
(nicotine replacement therapy, bupropion, varenicline, free quit line, and cessation support). 
Other countries provide a smaller combination of these therapies. Afghanistan, Oman, and 
Yemen only offer nicotine replacement therapies, Qatar provides insurance with full coverage 
for cessation interventions, and the majority offer partial or no financial assistance. 26 Cessation 
support and insurance coverage in each country is fully illustrated in Table 1. 
 Even if a country provides a specific cessation service, this does not mean that this 
practice is effective. For example, in Saudi Arabia, only 14.5% of primary care and family 
practice physicians report using the clinical practice guidelines for smoking cessation. An even 
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smaller percentage (6.5%) prescribe pharmacotherapy for smoking cessation, and 18.9% refer 
patients to cessation programs. 37 In the United Arab Emirates, only 24% of general practitioners 
were familiar with a community resource that they could refer patients to for support in pursuing 
smoking abstinence. 38 In Jordan, 38.8% of doctors and nurses were current smokers. Among 
male nurses and physicians, over 80% reported smoking. Approximately 64.1% shared the belief 
that health care professionals who smoke are less likely to advise patients to stop smoking. 39 In 
Syria, there is a complete lack of clinical practice standards for smoking cessation or cessation 
counseling training opportunities. 36 These studies illustrate the real challenges facing Arab 
populations interested in quitting, the need for more cessation interventions in Middle Eastern 
countries, and the need for more support from primary care providers for Arab patients that 
smoke. How this research translates to care of Arab immigrants upon resettlement in other 
countries, such as the US, is important and will be discussed next.   
Arab Immigration to the United States 
 Arab immigration to the US began in 1875. Syrian and Lebanese Christians entered due 
to economic hardship from a decline in the oil industry. The majority obtained unskilled jobs. 40 
By the late 1930s, this community has grown to between 130,000 and 350,000 individuals. In 
1945, a second wave of Arab immigration to the US began. This group of immigrants was from a 
wider span of Arabic countries, and the majority was Muslim. Most were educated professionals 
and immigrated due to regional conflicts, allowing them to enter a wealthier class than the 
previous immigrants. 41  
 Since late 1967, the majority of immigrants from Arabic countries have come to the US 
as refugees. 35 The United Nations High Commissioner for Refugees defines a refugee as 
someone who “owing to a well-founded fear of being persecuted for reasons of race, religion, 
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nationality, membership of a particular social group or political opinion, is outside the country of 
his nationality, and is unable to, or owing to such fear, is unwilling to avail himself of the 
protection of that country.” 36 Over the past 30 years, the US has resettled over 3 million 
refugees. 42 The Arab-Israeli War of 1967 and years of political turmoil following significantly 
increased the number of Middle Eastern refugees in the US, with the total population growing by 
more than seven-fold to almost 1.5 million in 2000. 35,43 In both 2009 and 2010, the largest 
people group resettled in the US was from Iraq. 39 In addition, Arabic was the most common 
language spoken by refugee arrivals between 2008 and 2013. Syrian and Iraqi refugees were two 
of the top five groups that obtained legal permanent resident status between 2001 and 2009. 42 
According to the Arab American Institute, a current approximation of the Arab-American 
population totals at around 3.7 million.44 
 It is important to note the significant influence the process of acculturation has upon 
immigrant Arabs’ smoking statuses. Immigrants who show less assimilation report that most of 
their friends are Arabs, they do not follow American customs, they feel more comfortable around 
Arabs than Americans, and are they highly dependent on nicotine. These Arab Americans 
smoked more than individuals of the same culture who conform to American standards or 
socialize mostly with Americans. 25 These results suggest that smoking cessation interventions 
for Arab Americans smoking at the highest rates should be culturally appropriate, as much of 
their nicotine dependence is dictated by their home country’s traditional behaviors. 
Justification for a Systematic Review 
 Little to no analysis has been performed to compare and identify the effectiveness of 
smoking cessation interventions among Arab populations. To this point, there have been few 
systematic reviews completed regarding interventions among minority populations, and these 
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results have not been confirmed among only Arab adolescents and adults. RW.ERROR - Unable to find 
reference:72 However, many recent events, including the September 11, 2001 attacks, the more 
recent 2015 Paris bombing, and the 2016 presidential campaign, have drawn increasing attention 
to this population. Unfortunately, much of this scrutiny has remained in the realms of media, 
politics, and public discourse and has yet to break into the medical and public health fields. 
 To best care for the recent increase in the Arab American population with improved 
cultural competence, an examination and comparison of current interventions targeting Arab 
populations is necessary. Ideally, this systematic review would analyze cigarette smoking 
cessation interventions targeting Arab adult migrants living outside of Arab countries. However, 
only two studies have been completed for this specific population, one of which was performed 
outside the US. 49,50 Therefore, I chose to analyze smoking cessation interventions occurring in 
Arab countries in hopes that the best techniques would be transferrable to programs for migrants. 
In summary, this systematic review analyzes the efficacy and comparative effectiveness of 
smoking cessation interventions for Arab adults, in hopes that the most successful care models 
will be replicated by the sections of America’s primary care workforce serving Arabs.   
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Methods 
 The focused question this systematic review addresses is “Among Arab adults, what is 
the efficacy and comparative effectiveness of smoking cessation interventions?”.  
Study Inclusion/Exclusion Criteria 
 The inclusion and exclusion criteria are shown in Table 2 organized by PICOTS criteria. 
To summarize, the population of interest is adult Arabs, defined as males and females 18 years or 
older, who smoke. For this review, an individual qualifies as an Arab if they are from one of the 
following countries: Afghanistan, Bahrain, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, 
Qatar, Saudi Arabia, Syria, Turkey, United Arab Emirates, or Yemen. Eligible interventions 
included behavioral therapy, pharmacotherapy, and combination therapy (i.e., combined 
behavioral therapy and pharmacotherapy). The outcome of interest was an objective measure of 
smoking or self-reported smoking behavior collected at least six months after the start of the 
intervention. The studies analyzed could take place in any country as long as the subjects were 
Arab and they were receiving treatment at a smoking cessation center. 
Table 2. PICOT Framework with Inclusion and Exclusion Criteria. 
 
 Criteria 
Category Include Exclude 
Population Male and female Arabs who are self-reported 
smokers and/or have smoked within the past 
30 days 
Arabic countries include: Afghanistan, 
Bahrain, Iran, Iraq, Israel, Jordan, Kuwait, 
Lebanon, Oman, Qatar, Saudi Arabia, Syria, 
Turkey, United Arab Emirates, Yemen 
Specific populations 
i.e. pregnant women, 
military personnel 
Children and 
adolescents (age <18 
years) 
vIntervention Behavioral therapy 
Pharmacotherapy 
Combination therapy (behavioral therapy plus 
pharmacotherapy, delivered simultaneously) 
All other interventions 
Comparison Studies with a concurrent control group, 
including a different therapy method, usual 
All other comparisons, 
including historical 
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care or no intervention; single group pre-post 
comparisons 
controls 
Outcome Objective measures of smoking or self-
reported smoking behavior at least 6 months 
after the start of the intervention 
All other outcomes 
Time period January 1990 to December 2015 Prior to 1990 
Setting Smoking cessation clinic in an Arab country All other settings 
Study design Randomized controlled trials, nonrandomized 
trials, cohort studies, single-group pre-post 
studies 
All other study 
designs 
Publication language English Languages other than 
English 
 
Data Sources and Searches 
 Information sources for the systematic evidence review included PubMed and Web of 
Science literature databases, as well as hand-searches of the references lists of key studies and 
systematic reviews. A full description of my search strategy is presented in Table 3. For the 
PubMed search, MeSH terms included “smoking cessation” and “Arabic”; filters for “Humans” 
and “English” were also used. and limited the search to articles published between January 1990 
and December 2015. A similar search was completed for the Scopus database (Table 3).  
Table 3. Literature Search Terms. 
 
Population Arab OR Arabs* OR Arabia* OR Afghanistan OR Bahrain OR Iran 
OR Iraq OR Israel OR Jordan OR Kuwait OR Lebanon OR Oman 
OR Qatar OR “Saudi Arabia” OR Syria OR Turkey OR “United 
Arab Emirates” OR Yemen 
Intervention Tobacco use cessation OR "Smoking cessation" OR ((Quit* OR 
Cessat* OR Reduc* OR Stop*) AND Smoking) 
Limits Humans 
English language 
January 1990 to December 2015 time period 
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Quality Criteria 
 This review used the US Preventive Services Task Force (USPSTF) quality rating criteria 
(Table 4). 51 These guidelines are specific to each study type, with randomized controlled trials 
and pre-post studies having very similar measures. After evaluating each full text study, a rating 
was assigned. A summary of the USPSTF ratings (i.e., good, fair and poor) are outlined in Table 
5. All studies rated “good” or “fair” were included; studies rated “poor” were excluded.  
Table 4. USPSTF Quality Criteria.51 
 
Initial assembly of comparable 
groups 
RCTs – adequate randomization, including concealment 
and whether potential confounders were distributed 
equally among groups 
Cohort studies – consideration of potential confounders 
with either restriction or measurement for adjustment in 
the analysis; consideration of inception cohorts 
Maintenance of comparable 
groups 
Includes attrition, crossovers, adherence, and 
contamination 
Important differential loss to 
follow-up or overall high loss to 
follow-up 
 
Measurements are equal, reliable, 
and valid 
Includes masking of outcome assessment 
Clear definition of interventions  
Important outcomes considered  
Analysis RCTs – intention-to-treat analysis 
Cohort studies – adjustment for potential confounders 
 
Table 5. USPSTF Quality Ratings. 51  
 
Good Meet all criteria – comparable groups are assembled initially and maintained throughout 
the study (follow-up at least 80%); reliable and valid measurement instruments are used 
and applied equally to the groups; interventions are spelled out clearly; important 
outcomes are considered; and appropriate attention to confounders in analysis 
Fair Any or all of the following problems are present without the important limitations noted 
in the poor category below – generally comparable groups are assembled initially but 
some question remains whether some (although not major) differences occurred in 
follow-up; measurement instruments are acceptable (although not the best) and 
generally applied equally; some but not all important outcomes are considered; and 
some but not all potential confounders are accounted for 
Poor Any of the following major limitations exist – groups assembled initially are not close 
to being comparable or are not maintained throughout the study; unreliable or invalid 
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measurement instruments are used or not applied equally among groups (including not 
masking outcome assessment); and key confounders are given little or no attention 
 
Study Selection 
  All titles and abstracts from database searches and hand-searches were reviewed by one 
reviewer to assess eligibility against criteria outlined in Table 2.  For all titles and abstracts that 
appeared to be eligible, full texts were retrieved and again reviewed against inclusion and 
exclusion criteria listed in Table 2.  
Data Extraction Process  
 I extracted data from articles selected for the systematic review after the full text review. 
A standard chart was used for each study. The following information was extracted from each 
study: study question, source of funding, source population, other population characteristics 
(e.g., percent female, mean age), study design, intervention, intervention setting, comparison, 
outcome measure, results, and others. All data abstracted from individual studies is shown in 
Appendix A and B, and a summary is provided in the Results (Table 6).  
Synthesis of Evidence 
 Results for all included studies were synthesized in both narrative format and summary 
tables, which can be found in Appendix B. Due to the small number of articles selected by this 
review, leading to the collection of a very diverse group of studies, meta-analysis was not 
appropriate. Instead, I provide a narrative interpretation of the overall quality, themes, and 
suggestions for future practice in the Results and Discussion sections. 
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Results 
Study Selection 
 Figure  1 shows the PRISMA flow diagram explaining the justification for exclusion from 
the review and the relevant numbers of articles. In total, 853 articles were identified from 
searches in PubMed and Scopus. After removing duplicates, a total of 517 articles remained. 
Title and abstract review yielded 46 eligible articles. Seven were excluded because they took 
place in specialized care settings as opposed to primary care or a clinic, seven were excluded for 
wrong outcome (e.g., no cessation rates reported), ten were excluded because they focused on a 
specific population (such as pregnant women or military personnel), four were excluded for 
wrong population, two were excluded due to low quality, two were excluded because they did 
not provide a description of the smoking cessation intervention, two were excluded because they 
did not use intervention strategies approved by this review, and three were excluded because 
they involved only adolescent smokers. Seven studies remained after the full text review for 
future data abstraction. 
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Figure 1. PRISMA Diagram. 
 
 
 
Study Characteristics  
 Six out of 7 included studies had a relatively small sample size (less than 350 
participants), and one study (evaluating a pharmacologic only intervention) enrolled a larter 
sample (> 16,000 participants). 52 The generally small sample size is most likely due to the 
intensive nature of behavioral therapy and the resources and time required to supply each 
participant with quality counseling.  
 The mean age of study participants was between 35 and 45 years in six studies; one study 
did not report the subjects’ age. 52 Literature shows that many smokers begin as early as age 15, 
suggesting that attempts to quit may be less effective in the age group of 35 to 45 years old due 
to the long period of time for which they have been exposed to nicotine. 53 In all but one study, 54 
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the majority of participants were male. One study intentionally excluded female participants as 
researchers believed that effective cessation techniques between genders would vary widely and 
that smoking is primarily a problem among men. 55  
 The baseline smoking levels and nicotine dependency for study participants varied 
widely in both numerical level and choice of measurement tool. Two used only the Fagerstrom 
scale. 56,57 One used a different scale with which to calculate nicotine dependence. 58 Two studies 
used only a self report of cigarettes smoked per day, with similar results at 20 and 21 cigarettes 
per day. 59,60 One study used both the Fagerstrom scale and the number of cigarettes smoked per 
day, but reported the results in ranges which made it hard to compare to other studies. 61 One 
study did not report the study participants’ baseline smoking status in any form. 62  
 Six out of seven studies included in this review used combination therapy as their 
primary intervention. The remaining study used just pharmacological therapy. 56 No studies 
employed only behavioral therapy. When analyzing the pharmacological components of each 
study, six out of seven studies offered nicotine replacement therapies as one of their medical 
interventions, including gum, tablets, and patches. The remaining study did not specify the type 
of nicotine replacement therapy offered. 62 Only one study did not offer any type of nicotine 
replacement therapy. 56 Four studies offered centrally-acting medicine. 56,58,59,61 Both bupropion 
and varenicline were offered in two separate studies. 56,58,61 For behavioral therapy, techniques 
ranged from 4 sessions to 23 sessions. 57,59 Six out of seven studies offered only group or 
individual counseling sessions. One study offered a wider variety of treatments, including 
seminars and follow-up activities. 61 Unfortunately, across all studies the behavioral therapies 
were described only briefly, making thorough analysis or replication virtually impossible. Only 
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three studies specified the duration of their behavioral or pharmacological interventions, which 
ranged from 8 weeks to unlimited access. 56,57,59  
 Two studies used a randomized trial design. 58,59 The remaining five studies were pre-post 
studies. This reoccurring opportunity for study participants to self-select the pharmacological 
treatment they used introduced bias, as the most motivated or educated patients might have 
chosen the methods previously shown to be effective. In one study, participants were excluded if 
they did not begin the method of their choice in 3-14 days after receiving the medication, which 
also may have introduced selection bias or willingness to quit bias. 56 Bias was also introduced 
by another study which only enrolled smokers who had previously taken part in a smoking 
intervention led by a clinic, instead of those in the general smoking population. 58  
 All studies measured abstinence as their outcome and reported this as a percent quit rate, 
but variations in how this abstinence was measured existed. Four studies used both self-reporting 
methods and biochemical test verification. 58-60,62 Three studies used only self-reporting of 
smoking habits, which introduces the chance for reporting bias. 56,57,61 The study characteristics 
are summarized in Table 8. Outcomes were collected between six months and five years after the 
intervention. A comparison of quit rates between study groups is shown in Table 7. 
 All of the studies included in this systematic review took place in smoking cessation 
clinics. This universal variable is extremely important in comparing the efficacy of each 
treatment, but does reduce the likelihood of replication in the primary care practice setting. Four 
out of seven studies took place in Iran. 57-60 Two studies took place in Turkey. 56,61  One study 
took place in Israel. 62 Overall, less than one third of the Middle Eastern countries are 
represented. 
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Table 6. Study Characteristics. 
 
Author, 
year 
Country 
Sample 
Size 
Mean Age 
Percent  
Female 
Baseline 
CPDa 
Study 
Design 
Duration 
Behavioral 
Intervention 
Pharmacologic 
Intervention 
Ahmadi et 
al., 200359 
Iran 
171 37.7 
0% 
19.93 RCT 
24 weeks 
23 weekly 
visits  
Gum, naltrexone, 
or clonidine 
Celik et 
al., 201556  
Turkey 
16,473 NSb 
29% 
NS Pre-post 
12 weeks 
N/A Varenicline or 
bupropion 
Heydari et 
al., 201258 
Iran 
308 42.4 
31.5% 
NS RCT 
NS 
4 sessions Nicotine patches, 
gum, tablets, or 
patches and gum 
Heydari et 
al., 201257 
Iran 
272 42.5 
41.2% 
NS Pre-post 
8 weeks 
Brief 
counseling 
Varenicline, 
patches, or 
control 
Oztuna et 
al., 200761 
Turkey 
350 37.4 
42.0% 
NS Pre-post 
NS 
Seminars, 4-5 
sessions, and 
follow-up 
activities 
Optional use of 
bupropion, 
patches, or gum 
Sharifi et 
al., 201260 
Iran 
132 39.0 
12.9% 
22.1 Pre-post 
Unlimited 
5 biweekly 
sessions 
Gum 
Sperber et 
al., 200062 
Israel 
89 41.8 
64.5% 
NS Pre-post 
NS 
8-10 weekly 
sessions 
Unspecified 
NRT 
aCPD = cigarettes per day 
bNS = not specified 
 
Quality Assessment 
 In regard to quality, two studies received a quality rating of good. 57,59 The remaining 
studies were rated fair in quality. All studies had an attrition rate of less than 20%, except for one 
study which had an attrition rate of 45%.63 
Results: Smoking Cessation 
 Due to the significant heterogeneity in terms of populations, interventions and outcome 
measures assessed in the seven included studies, it is difficult to compare the effectiveness and 
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efficacy of each type of intervention. However, some overall themes in relation to behavioral and 
pharmacological interventions can be gleaned and are discussed in detail below.  
 Two randomized controlled trials compared different interventions. One evaluated 
weekly behavioral therapy combined with the use of nicotine gum, naltrexone, or clonidine; the 
nicotine gum arm had a statistically significant improvement compared with the naltrexone and 
clonidine interventions at 6 months (RR 6.31; 95% CI 2.65, 15.06). 59 The second evaluated four 
sessions of behavioral therapy with the use of nicotine patches, gum, tablets, or patches and gum; 
no difference was found between the patches, gum, and tablets groups at 12 months. However, 
the patches and gum intervention had a statistically significant improvement compared to a 
single nicotine replacement therapy (RR 1.86; 95% CI 1.28, 2.72). 58 In the 5 pre-post studies, 
quit rates from baseline ranged from 12.9% to 34.6% over 6 months to 5 years.   
 In regards to the overall effectiveness of behavioral therapy, six out of seven studies 
employed this intervention and attested to its effectiveness, with quit rates of greater than 30% 
for several interventions. In addition, the  Celik et al. study which did not use behavioral therapy 
showed lower quit rates when using varenicline alone than when it is a part of a combination 
therapy. 56 The addition of a brief counseling session in the Heydari et al. study caused the quit 
rate to increase from 30% to 33% after 12 months, despite using varenicline for only 8 weeks 
instead of 12. 58  
 Pharmacological therapy also proved helpful. Without accounting for variances in study 
design, nicotine replacement therapies provided more effective support than centrally-acting 
agents when pursuing tobacco abstinence. In particular, combination approaches within this 
category proved very successful. The greatest quit rate, 62.5% at 1 year, occurred in the Heydari 
et al. study group which received both nicotine patches and gum. 57 Results varied on whether 
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nicotine gum or patches were more effective, with the Heydari et al. study suggesting both 
methods were equally effective and the Oztuna et al. study showing patches were more effective. 
57,61 The only study which compared the centrally-acting agents of interest to this review, 
varenicline and bupropion, produced statistically significant results supporting varenicline’s 
effectiveness over bupropion. 56  
Table 7. Study Results. 
 
Author, 
year 
Country 
Study 
Design 
Duration 
Behavioral 
Intervention 
Pharmacologic 
Intervention 
Outcome 
Timing 
Results (quit 
rate by 
study group) 
Quality 
Score 
Attrition 
Ahmadi et 
al., 200359 
Iran 
RCT 
24 weeks 
23 weekly 
visits  
Gum, 
naltrexone, or 
clonidine 
6 months Gum: 36.8% 
Naltrexone: 
5.3% 
Clonidine: 
5.3% 
Good 
0% 
Celik et 
al., 201556  
Turkey 
Pre-post 
12 weeks 
N/A Varenicline or 
bupropion 
1 year Varenicline: 
29.6% 
Bupropion: 
25.1% 
Fair 
20% 
Heydari et 
al., 201258 
Iran 
RCT 
NS 
4 sessions Nicotine 
patches, gum, 
tablets, or 
patches and 
gum 
1 year Gum: 25.8% 
Patches: 
16.7% 
Tablets:  
18.2% 
Patches and 
gum: 62.5% 
Fair 
9.4% 
Heydari et 
al., 201257 
Iran 
Pre-post 
8 weeks 
Brief 
counseling 
Varenicline, 
patches, or 
control 
1 year Varenicline: 
32.6% 
Patches: 25% 
Control: 
6.6% 
Good 
0% 
Oztuna et 
al., 200761 
Turkey 
Pre-post 
NS 
Seminars, 4-
5 sessions, 
and follow-
up activities 
Optional use of 
bupropion, 
patches, or gum 
5 years 34.6% (56 
patches, 6 
bupropion, 3 
gum) 
Fair 
44.6% 
Sharifi et 
al., 201260 
Iran 
Pre-post 
Unlimite
d 
5 biweekly 
sessions 
Gum 6 months 12.9% Fair 
0% 
Sperber et 
al., 200062 
Israel 
Pre-post 
NS 
8-10 weekly 
sessions 
Unspecified 
NRT 
1-3 years 33% Fair 
15% 
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aCPD = cigarettes per day 
bNS = not specified 
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Discussion  
 Arab migrants contribute significantly to their resettlement country's tobacco smoking 
rates. Although many studies have analyzed the prevalence and incidence of smoking cessation 
interventions among at-risk populations, very few have studied specifically Arab migrants. Due 
to this dearth in data, strategies used by physicians providing care in Arab countries were 
analyzed instead. A better understanding of the care received prior to resettlement in another 
country, such as the US, will help physicians to better care for these recently arrived populations. 
In summary, the primary goal of the collected data was to use current practices in Arab countries 
to make recommendations for US primary care physicians serving Arab refugees regarding the 
feasibility and most effective design of smoking cessation interventions and related research. 
Interpretation of Evidence 
 The evidence in this review supports combination therapy, or the use of both behavioral 
and pharmacological components, as the most effective strategy to help Arab populations reduce 
their tobacco use. This review recommends that clinicians prescribe nicotine replacement therapy 
as the pharmacological component for therapy due to the higher quit rates observed when 
comparing this tool to centrally-acting agents. The guidelines regarding behavioral therapy are 
less clear due to an unfortunate lack of description in the literature which was analyzed by this 
review. However, the importance of this component has been confirmed through the 
understanding of the relationship between tobacco and Arab culture that this review provides. 
Due to the family and community oriented nature of Arabic values and beliefs, personal support, 
encouragement, and accountability is very valuable during quit attempts. Because cigarette use is 
a culturally accepted, socially normal representation of friendship, hospitality, and maturity, 
smoking habits are often more deeply engrained in Arab individuals versus Westerners which 
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demands increased attention and social support from clinicians. The relational aspects of Arabic 
culture and the current lack of smoking cessation peer support show that the success of group 
and individual therapy is to be expected and should be capitalized upon during interventions in 
the US. There was no statistically significant difference between the results of the randomized 
controlled trials and the pre-post studies. 
Limitations of the Review 
 Despite careful methodological development and consistency of evaluation, several 
limitations of this review are present. First, due to time constraints, only articles published in 
English are included in this review. Because our population of focus primarily speaks Arabic and 
all of the studies which met our inclusion criteria took place overseas, it is likely additional 
evidence is available in other languages. As with any review of literature, this paper is also 
subject to reporting and publication bias.  
Limitations of the Body of Evidence 
 There are multiple limitations of this review’s compiled evidence. Firstly, the body of 
information regarding smoking cessation interventions among Arab patients is very small. This 
decreases the power of the results analyzed. Secondly, measurement bias is possible. Three out 
of the seven studies contained quit rate outcomes which were confirmed only by methods of self-
report by each participant. 56,57,61 Including scientific measurements, such as the carbon 
monoxide breath test, could have eliminated this potential for bias. In addition, selection bias is 
present. The majority of studies which take place among Arab populations recruit study 
participants from smoking cessation clinics. Individuals who attend appointments at such clinics 
have already shown a desire and motivation to quit, which increases their likelihood of quitting. 
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 In addition, the studies selected were not very specific regarding the methods for the 
behavioral interventions. Only two out of seven studies clearly illustrated who led the therapy 
sessions; one was led by an outreach worker and the second was led by a physician with a degree 
in health behaviors and education. 59,62 The variety in leaders and session designs have the 
potential to create considerable variation in results. Without specifying exact behavioral 
methods, it is impossible to account for these differences. Given the range of behavioral 
therapies and their general descriptions, this review is unable to identify the most effective 
technique or program length. The study designs of the articles included in this review also 
decrease the strength of the evidence. Only two studies were randomized. 58,59 Self-selection of 
smoking cessation therapies was practiced in the other five studies, most of which were 
observational, creating a bias in the results. Only one study utilized a control group. 58 The 
majority of the studies included were pre-post observational studies. This format may influence 
the behavior of smokers because specific methods used at certain cessation clinics could 
confound the effects of the individual aspects being studied. 
 Moreover, only 3 countries out of the previously identified 15 Arabic countries were 
represented. Despite being in a similar geographic area, each country has its own culture, 
smoking laws, cessation provisions, and insurance plans. Without a sampling more 
representative of the entire span of Arabic countries, it is hard to make assumptions about the 
Arabic population as a whole. In addition, little information was provided about the 
socioeconomic status of each participant. When planning the systematic review, this information 
was thought to be important and of value. Because the findings of this review are to be used to 
create programs for Arab refugees in the US, most of whom are of a low socioeconomic status, 
specifications regarding income and living situation would have been very helpful.  
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 An additional limitation of this review is its focus on only cigarette use. As stated in the 
introduction, Arabic populations have begun to increase their use of other harmful smoking 
options such as the water pipe. As these alternative smoking methods are most popular among 
women and youth, the predominance of male subjects in these studies further our inability to 
understand proper cessation methods for other types of tobacco.  
Implications for Practice 
 Due to the small pool of studies, this review can contribute only a few small findings 
towards the design of smoking interventions for Arabs living in the US. First, it can be deemed 
crucial that programs include both behavioral and pharmacological approaches. The community-
style culture of Arabs affirms the need for personal support during quit attempts. 25 It is important 
to provide culturally and linguistically appropriate cessation guides and feedback, just as each of 
the studies in this review were able to offer. In regards to pharmacotherapy, it is necessary to 
consider the financial aspect of purchasing centrally-acting medicines or nicotine replacement 
therapies. Most Arabic countries either do not offer these methods, or do not provide insurance 
coverage to help with their cost. 26 Arab immigrants in the US must be educated about these 
differences in our healthcare systems, and the opportunities for cost reduction in doctor and 
pharmacy bills should be explained accordingly.  
Implications for Research 
 While the implications for practice are few, the suggestions and ideas regarding future 
research are many. First, additional randomized trials using adult patients which use a universal 
measure to express each participant’s baseline smoking status or tobacco dependence should be 
completed in Middle Eastern countries. These studies should carefully analyze behavioral 
therapy methods. It may be unethical to include control groups, as interventions have been 
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proven to be successful in increasing abstinence in all of the literature in the review and 
researchers would have to deny this opportunity to a current smoker. Therefore, the comparison 
between different behavioral styles of therapy, including but not limited to the length and 
number of sessions, the type of personnel leading the session, the setting in which therapy takes 
place, the size of therapy groups, and the information taught at each lesson, should be 
emphasized. Studies should provide careful detail regarding the behavioral therapy they offer to 
patients, with emphasis on special cultural elements designed for Arab populations. Group or 
individual sessions should be led by qualified smoking cessation specialists. In addition, studies 
among smokers who have not previously participated in a smoking intervention should be 
attempted. Studies should also analyze the care provided at primary care clinics in the Middle 
East, as all seven of the included studies enrolled individuals who attend programs at smoking 
cessation clinics. Furthermore, it is important for researchers to expand their knowledge base 
beyond Iran, Turkey, and Israel by beginning to evaluate communities in new Middle Eastern 
countries with high smoking rates such as Jordan and Iraq. In addition, studies in Arab countries 
targeting women and different methods of tobacco use, such as water pipes, are required. 
Because an individual’s likelihood of smoking is influenced by the habits of those around them, 
a holistic understanding of tobacco habits inside the entire household and community is 
necessary. 
 After a deeper investigation regarding smoking cessation work abroad is completed, 
additional research should be performed in the US. Smoking cessation trials stateside will help to 
confirm or negate the findings from studies abroad. Studies in the US can also determine the 
influence assimilation has on an Arabic individual’s ability to quit smoking and any potential 
increases in hand rolled cigarette e-cigarette use. Results in US based smoking cessation trials 
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may also produce different results than those performed abroad due to the tobacco policies 
enforced by the US government. 
Conclusion 
 By analyzing current research regarding smoking cessation programs in the Middle East, 
smoking cessation specialists in the US can best design new interventions for Arab migrants. 
This review shows that combination therapy, including both behavioral and pharmacological 
elements, is most effective. The pharmacotherapy of choice is pairing of nicotine replacement 
patches and gum, allowing for short- and long-term withdrawal symptom relief. Unfortunately, 
information regarding specific behavioral therapy techniques and how to tailor these programs to 
the culture of Arabs is sparse. Results from additional randomized trials completed in Middle 
Eastern countries are necessary, and corresponding projects should be performed in the US as 
new findings develop. It is vital for these studies to be completed if US physicians wish to 
provide effective, culturally appropriate smoking cessation support for the Arab migrants in their 
patient populations. 
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Appendix A. Completed Data Extraction Forms 
Study 1 
COMBINATION 
Ahmadi, J et al. Twenty-four week maintenance treatment of 
cigarette smoking with nicotine gum, clonidine, and 
naltrexone. 
Study Question: To investigate the effect of nicotine gum, clonidine, and 
naltrexone in maintenance treatment of cigarette smoking 
Source of Funding: Not specified 
Source Population: Outpatient treatment center in the capital city Shiraz, Iran 
DSM-IV criteria for nicotine dependence, 10 cigarettes or 
more per day for at least one year 
Study Population: N = 171 
Mean age: 37.68 years 
Sex (% female): 0 
Baseline smoking status: 19.93 cigarettes per day 
Design: Prospective, double blind, randomized trial 
Intervention: Pharmacological: Nicotine gum (2 mg every 1-2 h for first 6 
weeks, 2-4 h for next 3 weeks, 4-8 h for last 15 weeks),  
Behavioral: Weekly visit from outreach worker 
Intervention Setting: Smoking cessation clinic 
Comparison: Oral naltrexone (50 mg daily), OR oral clonidine (0.4 mg 
daily) 
Same behavioral 
Measurement: Study groups: 3 groups of N=57 
Outcomes: abstinence at 24 weeks 
Outcome measures: self-report and test verification 
Results: 20.5% abstinence overall (36.8% nicotine gum, 19.3% 
clonidine, 5.3% naltrexone)  
Attrition: 0% 
Quality Score: Good 
 
Study 2 
PHARM 
Celik et al. Nationwide smoking cessation treatment support 
program – Turkey project.  
Study Question: To discover the effectiveness of a nation-wide community-
based smoking cessation intervention 
Source of Funding: Omega Contract Research Organization 
Source Population: All 81 cities in Turkey – 228 smoking cessation clinics, over 
400 physicians 
Study Population: N = 16,473 
Mean age: not specified 
Sex (% female): 29% 
Baseline smoking status: 16% with 0-4 fagerstrom score, 
45.6% with 5-7, 39.2% with 8-10 
Design: Single group pre-post study 
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Intervention: Free medicines provided: Varenicline (63.8%) and Bupropion 
(36.2%) for 12 weeks 
Intervention Setting: Smoking cessation clinic 
Comparison: None 
Measurement: Study groups: N/A 
Outcomes: Quit rate at 1-year follow-up 
Outcome measures: self-reported 
Results: Varenicline: 29.6% quit rate; Bupropion: 25.1% quit rate 
Attrition: 20% responded to 1-year follow-up 
Quality Score: Fair 
 
Study 3 
COMBINATION 
Heydari et al. Which form of nicotine replacement therapy is 
more effective for quitting smoking? A study in Tehran, Islamic 
Republic of Iran. 
Study Question: To compare quit rates of different formulations of nicotine 
replacement 
Source of Funding: Tobacco Prevention and Control Research Center, National 
Research Institute of Tuberculosis and Lung Diseases 
Source Population: Smoking cessation clinic patients at the Iranian National 
Research Institute 
Study Population: N = 308 
Mean age: 42.4 
Sex (% female): 31.5% 
Baseline smoking status: Fagerstrom score – 28.9% mild, 
36.0% moderate, and 35.1% severe 
Design: Pre-post study 
Intervention: 4 sessions of behavioral therapy + one type of NRT (patches, 
chewing gum, tablets, or both patches and gum) 
Intervention Setting: Smoking cessation clinic 
Comparison: None 
Measurement: Study groups: N=31 for patches, N=161 for gum, N=29 for 
tablets, N=87 for 2 types of NRT simultaneously 
Outcomes: 4 week, 6 month, 12 month quit assessment 
Outcome measures: self-reported 
Results: Gum: 84.0%/45.8%/25.8% (4 week/6 mo/12 mo) 
Patches:88.8%/91.7%/16.7% 
Tablets:88.0%/18.2%/18.2% 
Patches + gum:95.2%/67.5%/62.5% 
Attrition: 9.4% 
Quality Score: Fair 
 
Study 4 
COMBINATION 
Heydari et al. Quitting smoking with varenicline: parallel, 
randomised efficacy trial in Iran. 
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Study Question: To evaluate the effectiveness of varenicline for tobacco 
cessation 
Source of Funding: Ministry of Health and Food, Masih Daneshvari Hospital 
Research Institute, Tehran 
Source Population: Smokers attending tobacco cessation clinics in the Tobacco 
Prevention and Control Research Centre at Shahid Beheshti 
University of Medical Sciences in Tehran, Iran 
Study Population: N = 272 
Mean age: 42.5  
Sex (% female): 41.2% 
Baseline smoking status: nicotine dependence score of 5.5 +/- 
2.8 
Design: Randomized parallel clinical study 
Intervention: Brief counseling on cessation + nicotine patches 15 mg/day or 
varenicline 1 mg twice daily for 8 weeks 
Intervention Setting: Smoking cessation clinic 
Comparison: Brief counseling on cessation 
Measurement: Study groups: N=91 for behavioral only, N=92 for behavioral 
and nicotine, N=89 for behavioral and varenicline 
Outcomes: smoking status at 6 and 12 months 
Outcome measures: personal report and exhaled carbon 
monoxide measurement  
Results: Control: 13.2%/6.6% (6/12 months) 
Varenicline: 58.4%/32.6% 
NRT: 51.1%/25% 
Attrition: 0% 
Quality Score: Good 
 
Study 5 
COMBINATION 
Oztuna et al. Five-year outcomes for a smoking cessation 
clinic. 
Study Question: To determine what demographic characteristics and factors 
include the success of quitting among participants in a smoking 
cessation program 
Source of Funding: Not specified 
Source Population: Patients at smoking cessation clinic in Trabzon, Turkey 
18 years or older 
Study Population: N=350 
Mean age: 37.4 
Sex (% female): 42% 
Baseline smoking status: 5.4 Fagerstrom score; 24% smoke 
<10 cig per day, 53.1% smoke 11-20, 11.7% smoke 21-40, 
11.2% smoke >40 
Design: Pre-post study 
Intervention: Educational seminars + 4-5 behavioral counseling sessions + 
follow-up counseling and activities to help them abstain 
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Intervention Setting: Smoking cessation clinic 
Comparison: No comparison 
Measurement: Study groups: not specified 
Outcomes: quit rate at 5 years 
Outcome measures: self-reported 
Results: 34.6% quit rate (56 used nicotine patches, 3 used nicotine gum, 
6 used bupropion) 
Participants using NRT abstained from smoking 1.9 times 
longer than those without (95% CI: 1.2-2.9) 
Participants without withdrawal symptoms remained abstinent 
2.3 times longer (95% CI: 1.5-3.4) 
Attrition: 44.6% 
Quality Score: Fair 
 
Study 6 
COMBINATION 
Sharifi et al. Efficacy of harm education programs among 
patients of a smoking cessation clinic in Tehran, Iran. 
Study Question: To evaluate the effect of harm reduction programs on smoking 
patterns of subjects who presented to a smoking cessation 
clinic in Tehran, Iran 
Source of Funding: Tobacco Prevention and Control Research Center at Shaheed 
Beheshti Medical Science University 
Source Population: Tobacco Prevention and Control Research Center’s smoking 
cessation clinic in Tehran, Iran who had previously attended 
smoking cessation programs 
Study Population: N=132 
Mean age: approx 39 
Sex (% female): 12.9% 
Baseline smoking status: 22.1 cigarettes per day 
Design: Pre-post design interventional study 
Intervention: Group or individual behavioral therapy every 15 days + 2mg 
nicotine gum 
Intervention Setting: Smoking cessation clinic 
Comparison: None 
Measurement: Study groups: N=132 
Outcomes: 3rd and 6th month follow up = number of smoked 
cigarettes, level of expired CO, number of nicotine gum used 
Outcome measures: self-reported and CO measurement 
Results: 64.4% reduced cigarette use by at least half 
12.9% quit smoking 
Attrition: 0% 
Quality Score: Fair 
 
Study 7 
COMBINATION 
Sperber. Smoking cessation support groups in Israel: a long-
term follow up. 
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Study Question: To assess quitting rate of smokers who participated in smoking 
cessation groups, and to characterize predictors of success or 
failure over a 1-3 year follow-up period 
Source of Funding: Not specified 
Source Population: Israel 
Study Population: N=89 
Mean age: 41.8 
Sex (% female): 64.5% 
Baseline smoking status: not specified 
Design: Prospective interventional study 
Intervention: 8-10 behavioral sessions led by a physician with a master’s 
degree in health behavior and education + NRT 
Intervention Setting: Smoking cessation clinic 
Comparison: None 
Measurement: Study groups: N=89 
Outcomes: quit rate at least 1-3 years 
Outcome measures: self-report and carbon monoxide breath 
test 
Results: 33% quit 
Attrition: 15% 
Quality Score: Fair 
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Appendix B. Individual Study Analyses   
Pharmacological Therapy 
Study 1 
Citation Celik, I.; Yuce, D.; Hayran, M. et al. (November 23 2014). Nationwide 
smoking cessation treatment support program – Turkey project. Journal of 
Health Policy, 119:50-56. DOI: 10.1016/j.healthpol.2014.11.017 
Study Design Pre-post study 
Quality Fair 
Study Population N=16,473 
Age: not specified 
Sex (% female): 29% 
Baseline smoking status: 16% with 0-4 Fagerstrom score, 45.6% with 5-7, 
39.2% with 8-10 
Intervention Provision of free smoking cessation medicine for 12 weeks; 63.8% used 
Varenicline and 36.2% used bupropion 
Results Varenicline: 29.6% quit rate at 12 months 
Bupropion: 25.1% quit rate at 12 months 
 
 The Celik et al. study “Nationwide smoking cessation treatment support program – 
Turkey Project” is a prospective observational study published in the Journal of Health Policy 
which sought to determine the effectiveness of a nation-wide community-based smoking 
cessation intervention. Free smoking cessation medicine was offered to smokers in 81 cities at 
228 smoking cessation clinics in Turkey for a period of 12 weeks. Financial constraints often 
prohibit individuals from pursuing smoking cessation methods, especially in Turkey where 
insurance only provides partial coverage for medications. Approximately one-fourth of the 
16,473 study participants remained abstinent one year later.56 
 The study received a quality rating of fair due to several limitations. The number of 
subjects was extremely large, which prohibited researchers from taking into account personal 
smoking cessation challenges. These include comorbidities, nicotine dependence levels, health 
perceptions, psychosocial conditions, and economic aspects. Patients self-selected their nicotine 
replacement therapy and were required to begin treatment in 3-14 days after receiving the 
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medication, which may have introduced selection bias and willingness to quit bias. In addition, 
results were collected only by follow-up phone calls, with an attrition rate of 20%, and no 
biological measures were taken.  
 Overall, this study shows that pharmacological methods are successful in helping 
smokers remain abstinent over long periods of time. In addition, it provides an excellent 
illustration of how a health system can utilize its purchasing power to reduce drug costs and 
increase nationwide utilization of smoking cessation drugs.  
Behavioral Therapy 
 No studies using solely behavioral therapy matched this review’s inclusion criteria. 
Combination Therapy 
Study 1 
Citation Ahmadi, J.; Ashkani, H.; Ahmadi, M.; et al. (February 20 2003). Twenty-
four week maintenance treatment of cigarette smoking with nicotine gum, 
clonidine and naltrexone. Journal of Substance Abuse Treatment; 24:251-
255. DOI: 10.1016/S0740-5472(03)00027-8 
Study Design Prospective randomized trial 
Quality Score Good 
Study Population N=171 
Mean age: 37.68 years 
Sex (% female): 0% 
Baseline smoking status: 19.93 cigarettes per day 
Intervention Pharmacotherapy: 24 weeks of 
• Group 1: Nicotine gum (taper of 2 mg every 1-2 h to every 4-8 h) 
• Group 2: Oral naltrexone (50 mg daily) 
• Group 3: Oral clonidine (0.4 mg daily) 
Behavioral therapy: Weekly visit from outreach worker 
Results 20.5% quit rate overall at 6 months 
• 36.8% quit rate for nicotine gum  
• 19.3% quit rate for clonidine 
• 5.3% quit rate for naltrexone 
 
 The Ahmadi et al. study “Twenty-four week maintenance treatment of cigarette smoking 
with nicotine gum, clinidine, and naltrexone” is a prospective randomized trial published in the 
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Journal of Substance Abuse Treatment which investigates the effect of nicotine gum, clonidine, 
and naltrexone in the maintenance treatment of cigarette smoking. Pharmacotherapy and weekly 
behavioral therapy was offered to 171 patients at a smoking cessation clinic in Shiraz, Iran who 
smoked 10 cigarettes or more per day. Overall, 20.5% remained abstinent 6 months later. Among 
nicotine gum, clonidine, and naltrexone users, 36.8%, 19.3%, and 5.3% quit respectively.59 
 This study’s quality was labeled as good. It was the first study with three large groups in 
Iran, subjects were allocated randomly, and the attrition rate was 0%. However, the 
qualifications of the individuals who performed the behavioral counseling were not specified, 
suggesting this therapy may have been less effective than usual.  
 Overall, this study encourages the use of combination therapy and especially the selection 
of nicotine patches over the use of clonidine or naltrexone. No female patients were included in 
this study which may suggest results are only valid among male smokers. 
Study 2 
Citation Heydari, G.; Marashian, M.; Ahmady, A.E. et al. (2012). Which form of 
nicotine replacement therapy is more effective for quitting smoking? A 
study in Tehran, Islamic Republic of Iran. Eastern Mediterranean Health 
Journal, 18(10):1005-1010. 
Study Design Pre-post study 
Quality Score Fair 
Study Population N=308 
Mean age: 42.4 years 
Sex (% female): 31.5% 
Baseline smoking status: Fagerstrom score – 28.9% mild, 36.0% 
moderate, and 35.1% severe 
Intervention Pharmacotherapy: Nicotine patches, nicotine gum, nicotine tablets, or both 
patches and gum 
Behavioral therapy: 4 sessions 
Results Gum: 84.0% at 4 weeks, 45.8% at 6 months, 25.8% at 12 months  
Patches:88.8% at 4 weeks, 91.7% at 6 months, 16.7% at 12 months 
Tablets:88.0% at 4 weeks, 18.2% at 6 months, 18.2% at 12 months 
Patches and gum: 95.2% at 4 weeks, 67.5% at 6 months, 62.5% at 12 
months 
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 The Heydari et al. study “Which form of nicotine replacement therapy is more effective 
for quitting smoking? A study in Tehran, Islamic Republic of Iran” is an observational study 
published in the Eastern Mediterranean Health Journal which compares quit rates of different 
formulations of nicotine replacement therapy. Nicotine patches, gum, tablets, or both patches and 
gum and 4 sessions of behavioral therapy were offered to 308 smoking cessation clinic patients 
at the Iranian National Research Institute. At 12 months, 62.5% of patients using patches and 
gum, 25.8% of patients using only gum, 18.2% of patients using tablets, and 16.7% of patients 
using only patches remained abstinent. 57  
 This study was determined to have a quality score of fair. Participants were able to self-
select the nicotine replacement therapy they used, suggesting the most motivated patients might 
chose the most extensive package (patches and gum). In addition, quit rates were self-reported 
with an attrition rate of 9.4%.  
 Overall, this study illustrates the effectiveness of combination therapy, especially when 
multiple pharmacotherapies are used. The medications and therapy sessions in this trial were 
provided for free to patients, but researchers hope to discover in future trials if commitment to 
quit is greater if patients pay for part of the cost of treatment. However, cost is often a barrier to 
patients accessing care so the financial aspect should be balanced carefully.  
Study 3 
Citation Heydari, G.; Talischi, F.; Tafti, S.F. et al. (2012). Quitting smoking with 
varenicline: parallel, randomized efficacy trial in Iran. International 
Journal of Tuberculosis Lung Disease, 16(2):268-272. DOI: 
10.5588/ijtid.11.0183 
Study Design Randomized trial 
Quality Score Good 
Study Population N = 272 
Mean age: 42.5  
Sex (% female): 41.2% 
Baseline smoking status: nicotine dependence score of 5.5 +/- 2.8 
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Intervention Intervention group 
Pharmacotherapy: 8 weeks of  
• Group 1: Varenicline (1 mg bid) 
• Group 2: Nicotine patches (15 mg per day)  
Behavioral therapy: Brief counseling on cessation 
Control group 
Behavioral therapy: Brief counseling on cessation 
Results Varenicline: 58.4% quit rate at 6 months, 32.6% quit rate at 12 months 
Nicotine patches: 51.1% quit rate at 6 months, 25% quit rate at 12 months 
Control: 13.2% quit rate at 6 months, 6.6% quit rate at 12 months 
 
 The Heydari, Talischi et al. study “Quitting smoking with varenicline: parallel, 
randomized efficacy trial in Iran” is a randomized trial published in the International Journal of 
Tuberculosis Lung Disease which evaluates the effectiveness of varenicline for tobacco 
cessation. Pharmacotherapy consisting of varenicline or nicotine patches was assigned to each 
subject in the intervention group for 8 weeks; all subjects received brief behavioral counseling on 
cessation. The study included 272 smokers attending tobacco cessation clinics in Tehran, Iran. 
After 12 months, 32.6% of varenicline users, 25% of nicotine patch users, and 6.6% of control 
subjects remained abstinent.58 
 This study received a quality score of good. It was randomized and the attrition rate was 
0%. In addition, smoking cessation outcomes were measured by personal report and exhaled 
carbon monoxide measurements.  
 Overall, this study concluded that the addition of medical treatment to a smoking 
cessation plan is very helpful. Despite the very brief behavioral counseling provided, this study 
showed a higher success rate for patients accessing only behavioral therapy in comparison to 
studies completed in Western cultures. This suggests that personalized, interactive treatment 
plans may be especially effective among Arab populations.  
Study 4 
Citation Oztuna, F.; Can, G.; & Ozlu, T. (2007). Five-year outcomes for a smoking 
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cessation clinic. Respirology, 12:911-915. DOI: 10.1111/j.1440-
1843.2007.01127.x 
Study Design Pre-post study 
Quality Score Fair 
Study Population N=350 
Mean age: 37.4 years 
Sex (% female): 42% 
Baseline smoking status: 5.4 Fagerstrom score; 24% smoke <10 cig per 
day, 53.1% smoke 11-20, 11.7% smoke 21-40, 11.2% smoke >40 
Intervention Pharmacotherapy: optional use of bupropion, nicotine patches, or nicotine 
gum 
Behavioral therapy: educational seminars, 4-5 behavioral counseling 
sessions, and follow-up counseling and activities 
Results 34.6% quit rate at 5 years (56 used nicotine patches, 6 used bupropion, 3 
used nicotine gum) 
 
 The Oztuna et al. study “Five-year outcomes for a smoking cessation clinic” is an 
observation study published in the Journal of Respirology which sought to determine what 
demographic characteristics encourage the success of quitting among participants in a smoking 
cessation program. Extensive behavioral therapy and optional pharmacotherapy was offered to 
350 patients at a smoking cessation clinic in Trabzon, Turkey. After five years, 34.6% remained 
abstinent. Out of these subjects, 86.2% had selected nicotine patches as their nicotine 
replacement therapy of choice. Participants using a nicotine replacement therapy abstained from 
smoking 1.9 times longer than those without (95% CI: 1.2-2.9). In addition, participants without 
withdrawal symptoms remained abstinent 2.3 times longer (95% CI: 1.5-3.4).61 
 This study was determined to be of fair quality due to it’s attrition rate of 44.6%. In 
addition, patients were allowed to self-select their pharmacotherapy and self-report their follow-
up smoking habits.  
 Overall, this study commends the use of nicotine patches. It also demonstrates the 
effectiveness of a multidisciplinary smoking clinic with regular follow-up.  
Study 5 
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Citation Sharifi, H.; Kharaghani, R.; Emami, H. et al. (2012). Efficacy of harm 
reduction programs among patients of a smoking cessation clinic in 
Tehran, Iran. Archives of Iranian Medicine, 15(5):283-289. 
Study Design Pre-post design interventional study 
Quality Score Fair 
Study Population N=132 
Mean age: 39 years 
Sex (% female): 12.9% 
Baseline smoking status: 22.1 cigarettes per day 
Intervention Pharmacotherapy: Nicotine gum (2mg as needed) 
Behavioral therapy: Group or individual therapy every 15 days for 10 
weeks 
Results 12.9% quit rate at 6 months 
 
 The Sharifi et al. study “Efficacy of harm reduction programs among patients of a 
smoking cessation clinic in Tehran, Iran” is a pre-post design interventional study published in 
the Archives of Iranian medicine which evaluates the effect of harm reduction programs on 
smoking patterns of individuals presenting to a smoking cessation clinic in Tehran, Iran. 
Nicotine gum and both group and individual therapy was offered to 132 patients. Six months 
after the beginning of the intervention, 12.9% of participants had quit smoking. In addition, 
64.4% reduced their cigarette use by at least half.60 
 This study was deemed fair in its quality. The smoking cessation interventions offered 
during the first ten weeks were not structured, which decreases the impact of the results. In 
addition, all participants recruited for this study had attended an organized smoking cessation 
program before but failed to quit. This introduces selection bias and may be the cause behind the 
low quit rates. However, the combination of self-reported and biochemical outcome measures as 
well as the 0% attrition rate add strength to the study. 
 Overall, it is hard to quantify any specific recommendations for future smoking cessation 
programs among Arab populations due to the lack of clear organization in this intervention.  
Study 6 
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Citation Sperber, A.D.; Goren-Lerer, M.; Peleg, Aya et al. (May 2000). Smoking 
cessation support groups in Israel: A long-term follow-up. Israel Medical 
Association Journal, 2: 356-360. 
Study Design Prospective interventional study 
Quality Score Fair 
Study Population N=89 
Mean age: 41.8 years 
Sex (% female): 64.5% 
Baseline smoking status: not specified 
Intervention Pharmacotherapy: Nicotine replacement therapy 
Behavioral therapy: 8-10 sessions 
Results 33% quit at 1-3 years 
 
 The Sperber et al. study “Smoking cessation support groups in Israel: A long-term 
follow-up” is a prospective interventional study published in the Israel Medical Association 
Journal which assesses the quitting rates of smokers. Nicotine replacement therapy and 8-10 
behavioral therapy sessions were offered to 89 smokers living in Israel. Between one to three 
years after the intervention, 33% of participants remained abstinent from cigarettes.62 
 The quality of this study was determined to be fair. Participants had to express the desire 
to quit to meet eligibility for the study which may influence results. In addition, the small sample 
size and 15% attrition rate leaves room for type II error. However, behavioral sessions were led 
by a physician with a master’s degree in health behavior and education which helps to confirm 
the quality of the therapy. 
 Overall, this study suggests that smoking cessation support groups are effective methods 
for pursuing abstinence from cigarettes. Because the method of nicotine replacement is not 
specified, it is hard to tell if this study encourages the use of gum, patches, a combination of 
methods, or other techniques. 
 
